As­traZeneca, Dai­ichi Sankyo eye first ap­proval for TROP2 drug af­ter PhI­II breast can­cer suc­cess

As­traZeneca and Dai­ichi Sankyo’s TROP2-tar­get­ed an­ti­body-drug con­ju­gate has met a key end­point in the Phase III TRO­PI­ON-Breast01 tri­al, bring­ing it one step clos­er to po­ten­tial­ly com­pete against Gilead’s Trodelvy.

TRO­PI­ON-Breast01 is eval­u­at­ing the drug can­di­date, da­to-DXd, against in­ves­ti­ga­tors’ choice of chemother­a­py in 733 pa­tients with pre­vi­ous­ly-treat­ed in­op­er­a­ble or metasta­t­ic HR-pos­i­tive, HER2-neg­a­tive breast can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER